Download - 24.antiplatelet drugs
Transcript
![Page 1: 24.antiplatelet drugs](https://reader033.vdocuments.us/reader033/viewer/2022061610/58f05bc31a28aba90f8b4569/html5/thumbnails/1.jpg)
Antiplatelet drugs
Interfere with platelet
function
![Page 2: 24.antiplatelet drugs](https://reader033.vdocuments.us/reader033/viewer/2022061610/58f05bc31a28aba90f8b4569/html5/thumbnails/2.jpg)
Classification1. TXA2 synthesis inhibitor: Aspirin
2. Others: Dipyridamole, clopidogrel, ticlopidine
abciximab
![Page 3: 24.antiplatelet drugs](https://reader033.vdocuments.us/reader033/viewer/2022061610/58f05bc31a28aba90f8b4569/html5/thumbnails/3.jpg)
ASPIRIN Low dose aspirin (75-150 mg/day)- selectively produce antiplatelet activity
Irreversibly inhibits thromboxane synthase
Reduces TXA2 production antiplatelet activity
![Page 4: 24.antiplatelet drugs](https://reader033.vdocuments.us/reader033/viewer/2022061610/58f05bc31a28aba90f8b4569/html5/thumbnails/4.jpg)
Mechanism of action Membrane phospholipids ↓Arachidonic acid ↓cyclic endoperoxides ↓ Thromboxane synthase TXA2 (platelet aggregation)
AspirinInhibits
![Page 5: 24.antiplatelet drugs](https://reader033.vdocuments.us/reader033/viewer/2022061610/58f05bc31a28aba90f8b4569/html5/thumbnails/5.jpg)
Therapeutic uses1. Myocardial infarction (MI)2. Prevent MI in high risk patients3. Reduce incidence of stroke in high risk patients
![Page 6: 24.antiplatelet drugs](https://reader033.vdocuments.us/reader033/viewer/2022061610/58f05bc31a28aba90f8b4569/html5/thumbnails/6.jpg)